Polycythemia vera in its advanced stages shifts from a disease of too many blood cells to one of bone marrow failure, and that transition reshapes virtually every symptom a patient experiences. The disease can progress along two main paths: transformation into secondary myelofibrosis, sometimes called the “spent phase,” or, less commonly, transformation into acute leukemia. Over a 20-year period, roughly 16% of patients develop fibrotic progression and about 4% undergo leukemic transformation.1PubMed Central. Polycythemia vera: historical oversighted, diagnostic details, and therapeutic views What patients and families often want to know is what that progression actually feels like, what symptoms signal it, and what can still be done.
What “End Stage” Actually Means in Polycythemia Vera
Polycythemia vera is a chronic blood cancer that, for many people, remains relatively stable for years or even decades. Median survival exceeds 35 years in younger patients.2PubMed Central. Polycythemia vera: historical oversighted, diagnostic details, and therapeutic views But PV is a progressive disease, and its natural history can be disrupted by serious complications. Clinicians don’t typically use the phrase “end stage” the way it’s used for, say, kidney failure or heart disease. Instead, advanced PV is described in terms of its transformation: post-PV myelofibrosis, blast-phase disease, or leukemic transformation.
In the spent phase, the bone marrow that once overproduced red blood cells becomes scarred with fibrous tissue. This scarring gradually chokes off normal blood cell production. Up to 20% of PV patients eventually develop secondary myelofibrosis or transform into overt leukemia.3Nature. Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2 Leukemic transformation specifically is less common, occurring in roughly 2% to 4% of PV patients over ten years, but it carries a grim prognosis when it does happen.4PubMed Central. Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review
The Shift from Too Many Blood Cells to Too Few
Early PV is defined by excess: too many red blood cells, often too many white cells and platelets. End-stage disease flips that picture. As fibrosis replaces functional bone marrow, patients develop cytopenias, meaning their blood counts drop. Red blood cell production falls, causing anemia. Platelet counts can plummet, raising the risk of bleeding. White blood cell production becomes disordered as well, which compromises the immune system.
This is one of the most disorienting transitions for patients who have spent years managing high blood counts. A person who previously needed regular phlebotomies (blood draws to lower red cell volume) may suddenly become transfusion-dependent, needing blood put in rather than taken out. The anemia of spent-phase PV causes profound fatigue that is qualitatively different from the fatigue earlier in the disease. It doesn’t respond to rest and tends to worsen steadily.
Several factors predict who is more likely to progress to this fibrotic stage. A large study found that early bone marrow fibrosis, a high white blood cell count, an enlarged spleen you can feel on exam, and an abnormal set of chromosomes all independently raised the risk. In that analysis, patients who already had some degree of bone marrow scarring were roughly three times as likely to develop full-blown myelofibrosis.5PubMed Central. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations Older age, high white cell counts, and certain additional genetic mutations beyond the standard JAK2 driver mutation are also recognized as negative prognostic markers.6Nature. Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2
Constitutional Symptoms and How They Escalate
PV causes a recognizable cluster of symptoms even in its earlier phases, but these intensify as the disease advances. Data from a large U.S. registry found that the five most commonly reported symptoms were fatigue, early satiety (feeling full after eating very little), physical inactivity, itching, and difficulty concentrating. Fatigue was by far the most universal, with about 80% of patients reporting at least mild fatigue regardless of how well their blood counts were controlled.7PubMed Central. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study Other symptoms reported at lower frequencies included night sweats, abdominal discomfort, bone pain, unintentional weight loss, and fevers.8PubMed Central. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
A separate study looking specifically at symptom severity found that night sweats, fatigue, and abdominal discomfort ranked as the most intense complaints, while weight loss, itching, early satiety, and fever, though present, were perceived as less severe.9Documenta Haematologica – Revista Romana de Hematologie. The Impact of Current Treatment on The Symptomatology and Complications of Patients with Polycythemia Vera As PV transforms into myelofibrosis, every one of these symptoms tends to ramp up. The drenching night sweats, persistent fevers, and rapid weight loss seen in advanced myelofibrosis collectively signal a high inflammatory state driven by the diseased marrow. These so-called constitutional symptoms can be debilitating enough to dominate a patient’s daily life even before other complications set in.
Bone pain also worsens in the spent phase. As the marrow fills with scar tissue, and as extramedullary hematopoiesis (blood cell production outside the marrow) revs up in the spleen and liver, patients often describe deep, aching bone pain that is difficult to control with standard painkillers.
Aquagenic Pruritus and Its Persistence
Itching triggered by water contact, known as aquagenic pruritus, is one of the most distinctive and distressing symptoms of PV. In a study of 441 PV patients, roughly two-thirds reported this symptom, and in nearly 65% of those, the itching had started almost three years before the PV diagnosis itself. Most described the sensation as itching, though some experienced tickling, stinging, or burning. It predominantly affected the trunk and the upper parts of the arms and legs.10PubMed. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients
What’s striking is how poorly this symptom responds to treatment. Only about a quarter of patients received any pruritus-specific therapy, mostly antihistamines, which helped roughly half of them. Standard PV-directed treatments like phlebotomy or cytoreductive drugs resolved the itching in just 5.6% of cases. Nearly 15% of patients described their pruritus as “unbearable,” and those with aquagenic pruritus reported worse overall health, more fatigue, more pain, and more shortness of breath compared to PV patients without it.11PubMed. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients In advanced disease, pruritus can either persist or be overtaken by more dominant symptoms of marrow failure and splenomegaly.
Massive Spleen Enlargement and Extramedullary Hematopoiesis
As the bone marrow fails, the body tries to compensate. Blood cell production migrates to the spleen and liver, a process called extramedullary hematopoiesis. The spleen, in particular, can swell to enormous proportions, sometimes filling much of the abdominal cavity. This is one of the hallmark features of post-PV myelofibrosis and causes a cascade of symptoms on its own: intense abdominal discomfort, early satiety (because the enlarged spleen physically presses on the stomach), and pain radiating to the left shoulder.
While the spleen and liver are the most common sites of extramedullary hematopoiesis, this process can occasionally occur in less expected places, including the nervous system. There are reports of hematopoietic tissue accumulating along the dura (the membrane surrounding the brain and spinal cord) or within bony structures around the skull, leading to compression of the brain, cranial nerves, spinal cord, or nerve roots.12MedLink Neurology. Polycythemia vera and its neurologic manifestations These neurologic complications are rare but can produce symptoms ranging from headaches and vision changes to limb weakness or numbness, depending on where the compression occurs.
Splenic enlargement is also an independent risk factor for fibrotic progression. In the study mentioned earlier on bone marrow fibrosis prognostics, palpable splenomegaly roughly doubled the risk of progressing to myelofibrosis, and this remained significant even after accounting for other factors.13PubMed Central. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
Thrombosis and Bleeding in Advanced Disease
The risk of blood clots is one of the most dangerous aspects of PV throughout its course, and it remains a leading cause of serious illness and death. Both arterial clots (strokes, heart attacks) and venous clots (deep vein thrombosis, pulmonary embolism) occur at elevated rates. Over 20 years, about a quarter of PV patients experience a thrombotic event.14PubMed Central. Polycythemia vera: historical oversighted, diagnostic details, and therapeutic views A prior history of thrombosis is one of the strongest independent predictors of death, roughly doubling the hazard.15PubMed. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
Bleeding complications, though less common and usually less severe than clotting, also occur, particularly in patients whose platelet counts run very high. In those patients, a problem with a clotting protein called von Willebrand factor can develop, leading to mucocutaneous bleeding: easy bruising, nosebleeds, bleeding gums, and sometimes serious gastrointestinal hemorrhage.16Best Practice & Research Clinical Haematology. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention In the spent phase, as platelet production becomes unreliable and counts swing between high and dangerously low, patients can experience both clotting and bleeding complications within a short period. Managing anticoagulation in someone who is simultaneously at risk for both is one of the trickiest clinical challenges in end-stage PV.
Organ Damage Beyond the Blood
Advanced PV doesn’t confine its damage to blood counts. Years of abnormally thick blood, elevated inflammatory signaling, and thrombotic microangiopathy can take a toll on solid organs. The kidneys are one target. A study of renal involvement in PV identified patients with advanced chronic kidney disease, including some at stage 3b or 4. The underlying kidney damage included various types of glomerular disease as well as ischemic renal injury, consistent with the chronic vascular stress PV places on the kidneys. During follow-up, one patient with uncontrolled PV who went on to develop secondary myelofibrosis died, while others remained alive but with ongoing chronic kidney disease.17PubMed Central. Clinical and Pathological Features of Renal Presentations in Polycythemia Vera
Cardiovascular damage accumulates as well. The combination of high hematocrit (thick blood), elevated white cells, and activated platelets creates an environment that promotes atherosclerosis and microvascular disease over time. Pulmonary hypertension, though less well studied in PV than in primary myelofibrosis, can develop as a consequence of chronic thromboembolism or of the disease’s direct effects on the pulmonary vasculature. These organ-level complications are not always symptomatic until advanced stages, which is part of why regular monitoring matters even when a patient feels relatively well.
Increased Infection Risk
People with PV are more susceptible to infections than the general population, and this risk increases as the disease advances and as treatment suppresses immune function. A large population-based study of over 8,300 patients with myeloproliferative neoplasms found that PV patients had roughly 1.7 times the infection risk of matched controls. The pattern held across bacterial, viral, and fungal infections. The risk of sepsis was even more pronounced, at about 2.6 times the rate seen in the general population.18PubMed Central. Risk of infections in patients with myeloproliferative neoplasms – a population-based cohort study of 8 363 patients
For context, the infection risk in PV was comparable to that in essential thrombocythemia but substantially lower than in primary myelofibrosis, where the risk jumped to roughly 3.7 times controls.19PubMed Central. Risk of infections in patients with myeloproliferative neoplasms – a population-based cohort study of 8 363 patients When PV transforms into secondary myelofibrosis, the infection risk profile likely shifts closer to that of primary myelofibrosis, though this specific transition hasn’t been studied as thoroughly. In practical terms, infections in late-stage PV can be more difficult to fight off, more likely to progress to sepsis, and more often a contributing factor in death.
What Treatment Can Still Achieve in Advanced Disease
Even in advanced PV, treatment can meaningfully control symptoms and slow progression. Ruxolitinib, a JAK inhibitor, has become a cornerstone of therapy for PV patients who don’t respond well to older treatments like hydroxyurea. In the pivotal RESPONSE trial, ruxolitinib dramatically outperformed standard therapy: about 60% of patients on ruxolitinib achieved hematocrit control compared to 20% on standard therapy, and nearly 40% had substantial spleen shrinkage compared to just 1% in the control arm. Symptom relief was also substantial, with about half of patients on ruxolitinib achieving at least a 50% reduction in their total symptom score.20PubMed Central. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Follow-up data showed that these benefits were durable, with responses holding for at least 80 weeks in many patients.21PubMed. Ruxolitinib: A Review in Polycythaemia Vera
Once PV has transformed into secondary myelofibrosis, the treatment landscape shifts. Ruxolitinib is also approved for myelofibrosis and has demonstrated reductions in spleen size, symptom burden, and improved overall survival in that setting.22PubMed Central. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Allogeneic stem cell transplantation remains the only potentially curative option for post-PV myelofibrosis, but it carries significant risks and is typically reserved for younger, fitter patients with high-risk disease features. For the majority who are not transplant candidates, the goal shifts to managing symptoms, maintaining transfusion independence as long as possible, and preventing complications.
If the disease transforms into acute leukemia, treatment options become quite limited. Acute leukemia arising from PV tends to be resistant to standard chemotherapy regimens and carries a poor prognosis. Clinical trials exploring newer targeted therapies may be available, but the honest reality is that leukemic transformation is the most feared outcome in PV for a reason.
The Burden on Caregivers and Daily Life
Advanced PV takes a toll that extends well beyond the patient. A survey of over 900 people with myeloproliferative neoplasms found that more than half had needed help from a caregiver at some point because of their disease. Patients who required frequent caregiving had dramatically higher symptom burdens: their average symptom scores were more than double those of patients who had never needed a caregiver. Among caregivers who were employed, about a quarter had reduced their work hours, and roughly 7% had quit a job or taken early retirement to provide care.23International Archives of Nursing and Health Care. Impact on Caregivers of Patients with Myeloproliferative Neoplasms (MPNs) in the United States: Results from the Living with MPNs Survey
The symptom burden in advanced PV doesn’t always track neatly with blood test results, which can be frustrating for patients and caregivers alike. Data from the REVEAL study showed that fatigue severity was largely independent of whether blood counts were well controlled.24PubMed Central. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study A patient whose labs look stable may still feel terrible. This disconnect is one reason why comprehensive palliative care, focused on symptom management, functional status, and psychosocial support, has been increasingly recognized as essential for people living with MPNs, not just at the end of life but throughout the disease course.25Mary Ann Liebert, Inc., publishers / PubMed Central. Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms
Recognizing the Transition
One of the most practical questions for patients and families is how to tell when PV is moving into its advanced phases. The transition is not always dramatic. Some of the clearest signals include a falling hematocrit that no longer needs phlebotomy, a rising or newly palpable spleen, worsening constitutional symptoms like unintentional weight loss and drenching night sweats, and a blood smear that starts showing teardrops-shaped red cells and immature white cells being pushed out of a fibrotic marrow. A bone marrow biopsy showing increasing fibrosis is the definitive confirmation, but doctors often suspect the transition on clinical grounds before ordering one.
Patients sometimes assume that not needing phlebotomy anymore is a good sign, that the disease is “burning out.” In reality, it often reflects the opposite: the marrow is failing. If you or someone you care for has PV and notices that blood counts are drifting downward, fatigue is worsening, or the spleen is growing, these are reasons to have a frank conversation with your hematologist about disease staging and what comes next. Symptom assessment tools like the MPN-SAF, which scores symptoms on a standardized scale, can help make those conversations more concrete by tracking changes over time rather than relying on vague impressions.26Blood. Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera